Plain-English translation of NCT07583888 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new drug combination called —made up of five different medications (Venetoclax, Azacitidine, Semustine, Cytarabine, and Busulfan)—to prepare elderly patients (age 60 and older) with acute myeloid leukemia for a blood stem cell transplant. The researchers want to see if this medication combination works well and is safe for older patients who need this transplant as treatment for their leukemia.
Acute myeloid leukemia is a serious blood cancer, and stem cell transplants can help treat it. However, preparing a patient's body for transplant is challenging, especially for older adults who may not tolerate standard treatments well. This trial is testing whether this new medication combination can be a safer and more effective way to prepare elderly patients for transplant.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new drug combination as preparation (called conditioning) for your stem cell transplant. This happens at one of several hospitals in China participating in the study. The research team will closely monitor you throughout the process, checking your blood counts, organ function, and how well you're tolerating the treatment, as well as watching for any side effects like infection or damage to your organs.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China